Health alliance for prudent prescribing and yield of antibiotics in a patient-centred perspective (HAPPY PATIENT): a before-and-after intervention and implementation study protocol.


Journal

BMC primary care
ISSN: 2731-4553
Titre abrégé: BMC Prim Care
Pays: England
ID NLM: 9918300889006676

Informations de publication

Date de publication:
02 05 2022
Historique:
received: 26 01 2022
accepted: 18 04 2022
entrez: 3 5 2022
pubmed: 4 5 2022
medline: 6 5 2022
Statut: epublish

Résumé

Excessive and inappropriate use of antibiotics is the most important driver of antimicrobial resistance. The aim of the HAPPY PATIENT project is to evaluate the adaptation of European Union (EU) recommendations on the prudent use of antimicrobials in human health by evaluating the impact of a multifaceted intervention targeting different categories of healthcare professionals (HCPs) on common community-acquired infectious diseases, especially respiratory and urinary tract infections. HAPPY PATIENT was initiated in January 2021 and is planned to end in December 2023. The partners of this project include 15 organizations from 9 countries. Diverse HCPs (doctors, nurses, pharmacists, and pharmacy technicians) will be audited by the Audit Project Odense (APO) method before and after an intervention in four different settings: general practice, out of hours services, nursing homes and community pharmacies in four high antibiotic prescribing countries (France, Poland, Greece, and Spain) and one low prescribing country (Lithuania). About 25 individuals from each professional group will be recruited in each country, who will register at least 25 patients with community-acquired infections during each audit period. Shortly before the second registration participants will undertake a multifaceted intervention and will receive the results from the first registration to allow the identification of possible quality problems. At these meetings participants will receive training courses on enhancement of communication skills, dissemination of clinical guidelines with recommendations for diagnosis and treatment, posters for the waiting rooms, and leaflets for patients. The results of the second registration will be compared with those obtained in the first audit. HAPPY PATIENT is an EU-funded project aimed at contributing to the battle against antibiotic resistance through improvement of the quality of management of common community-acquired infections based on interventions by different types of HCPs. It is hypothesized that the use of multifaceted strategies combining active intervention will be effective in reducing inappropriate prescribing and dispensing of antibiotics. EU Health programmes project database https://webgate.ec.europa.eu/chafea_pdb/health/projects/900024/summary ; date of registration: 1 January 2021.

Sections du résumé

BACKGROUND
Excessive and inappropriate use of antibiotics is the most important driver of antimicrobial resistance. The aim of the HAPPY PATIENT project is to evaluate the adaptation of European Union (EU) recommendations on the prudent use of antimicrobials in human health by evaluating the impact of a multifaceted intervention targeting different categories of healthcare professionals (HCPs) on common community-acquired infectious diseases, especially respiratory and urinary tract infections.
METHODS/DESIGN
HAPPY PATIENT was initiated in January 2021 and is planned to end in December 2023. The partners of this project include 15 organizations from 9 countries. Diverse HCPs (doctors, nurses, pharmacists, and pharmacy technicians) will be audited by the Audit Project Odense (APO) method before and after an intervention in four different settings: general practice, out of hours services, nursing homes and community pharmacies in four high antibiotic prescribing countries (France, Poland, Greece, and Spain) and one low prescribing country (Lithuania). About 25 individuals from each professional group will be recruited in each country, who will register at least 25 patients with community-acquired infections during each audit period. Shortly before the second registration participants will undertake a multifaceted intervention and will receive the results from the first registration to allow the identification of possible quality problems. At these meetings participants will receive training courses on enhancement of communication skills, dissemination of clinical guidelines with recommendations for diagnosis and treatment, posters for the waiting rooms, and leaflets for patients. The results of the second registration will be compared with those obtained in the first audit.
DISCUSSION
HAPPY PATIENT is an EU-funded project aimed at contributing to the battle against antibiotic resistance through improvement of the quality of management of common community-acquired infections based on interventions by different types of HCPs. It is hypothesized that the use of multifaceted strategies combining active intervention will be effective in reducing inappropriate prescribing and dispensing of antibiotics.
STUDY REGISTRATION
EU Health programmes project database https://webgate.ec.europa.eu/chafea_pdb/health/projects/900024/summary ; date of registration: 1 January 2021.

Identifiants

pubmed: 35501712
doi: 10.1186/s12875-022-01710-1
pii: 10.1186/s12875-022-01710-1
pmc: PMC9063370
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102

Informations de copyright

© 2022. The Author(s).

Références

Fam Pract. 2021 Jun 17;38(3):259-264
pubmed: 33215207
J R Coll Gen Pract. 1972 May;22(118):310-5
pubmed: 5073372
Scand J Prim Health Care. 2005 Mar;23(1):42-6
pubmed: 16025873
Elife. 2018 Dec 18;7:
pubmed: 30560781
BMC Med. 2010 Oct 20;8:63
pubmed: 20961442
BMC Fam Pract. 2011 Jun 20;12:52
pubmed: 21689406
Curr Opin Infect Dis. 2021 Oct 1;34(5):423-431
pubmed: 34267046
Fam Pract. 2006 Apr;23(2):198-202
pubmed: 16243954
Br J Gen Pract. 2022 Apr 28;72(718):235-236
pubmed: 35483949
Antibiotics (Basel). 2017 Dec 14;6(4):
pubmed: 29240687
PLoS One. 2013 Oct 23;8(10):e76691
pubmed: 24194845
Antibiotics (Basel). 2013 Sep 16;2(3):439-49
pubmed: 27029312
Mayo Clin Proc. 2011 Feb;86(2):156-67
pubmed: 21282489
J Antimicrob Chemother. 2021 Jul 26;76(12 Suppl 2):ii68-ii78
pubmed: 34312659
BMJ Open. 2015 Sep 30;5(9):e008592
pubmed: 26423853
J Clin Pharm Ther. 2018 Feb;43(1):59-64
pubmed: 28833324
Infect Drug Resist. 2019 Dec 20;12:3903-3910
pubmed: 31908502

Auteurs

Anders Bjerrum (A)

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol, Barcelona, Spain.

Ana García-Sangenís (A)

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol, Barcelona, Spain.

Daniela Modena (D)

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol, Barcelona, Spain.

Gloria Córdoba (G)

University of Copenhagen, Copenhagen, Denmark.

Lars Bjerrum (L)

University of Copenhagen, Copenhagen, Denmark.

Athina Chalkidou (A)

University of Copenhagen, Copenhagen, Denmark.

Jesper Lykkegaard (J)

Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense, Denmark.

Malene Plejdrup Hansen (MP)

Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense, Denmark.

Jens Søndergaard (J)

Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense, Denmark.

Jørgen Nexøe (J)

Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense, Denmark.

Ingrid Rebnord (I)

NORCE Norwegian Research Centre AS, Bergen, Norway.

Isabel Sebjørnsen (I)

NORCE Norwegian Research Centre AS, Bergen, Norway.

Jette Nygaard Jensen (JN)

The Department of Clinical Microbiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.

Matilde Bøgelund Hansen (MB)

The Department of Clinical Microbiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.

Katja Taxis (K)

Rijksuniversiteit Groningen, Groningen, The Netherlands.

Maarten Lambert (M)

Rijksuniversiteit Groningen, Groningen, The Netherlands.

Ria Benko (R)

Rijksuniversiteit Groningen, Groningen, The Netherlands.

Beatriz González López-Valcárcel (B)

University of Las Palmas de Gran Canaria and Fundación Canaria Parque Científico Tecnológico, Las Palmas, Spain.

Fabiana Raynal (F)

University of Las Palmas de Gran Canaria and Fundación Canaria Parque Científico Tecnológico, Las Palmas, Spain.

Nieves Barragán (N)

Spanish Society for Family and Community Medicine, Barcelona, Spain.

Pia Touboul (P)

Department of Public Health, Nice University Hospital, Nice, France.

Pascale Bruno (P)

Department of Public Health, Nice University Hospital, Nice, France.

Ruta Radzeviciene (R)

Ltd Mano Seimos Gydytojas (My Family Doctor), Klapeida, Lithuania.

Lina Jaruseviciene (L)

Lithuanian University of Health Sciences, Kaunas, Lithuania.

Auste Bandzaite (A)

Lithuanian University of Health Sciences, Kaunas, Lithuania.

Maciek Godycki-Cwirko (M)

Centre for Family and Community Medicine, the Faculty of Health Sciences, The Medical University of Lodz, Lodz, Poland.

Anna Kowalczyk (A)

Centre for Family and Community Medicine, the Faculty of Health Sciences, The Medical University of Lodz, Lodz, Poland.

Christos Lionis (C)

Clinic of Social and Family Medicine, School of Medicine, University of Crete, Rethymno, Greece.

Maria-Nefeli Karkana (MN)

Clinic of Social and Family Medicine, School of Medicine, University of Crete, Rethymno, Greece.

Marilena Anastasaki (M)

Clinic of Social and Family Medicine, School of Medicine, University of Crete, Rethymno, Greece.

Jamie Coleman (J)

European Association for Clinical Pharmacology and Therapeutics, London, UK.

Helena Glasová (H)

European Association for Clinical Pharmacology and Therapeutics, London, UK.

Michiel van Agtmael (M)

European Association for Clinical Pharmacology and Therapeutics, London, UK.

Pierre Tattevin (P)

Rennes University Hospital, Rennes, France.

Alicia Borràs (A)

University Institute for Patient Care, Barcelona, Spain.

Carl Llor (C)

Institut Català de la Salut, Via Roma Health Centre, c. Manso, 19, 3rd floor, 08015, Barcelona, Spain. carles.llor@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH